Syntekabio said that it will develop
immunotherapy agents jointly with CHA Hospital by using the company’s
artificial intelligence (AI) platform Deep Matcher.
The two institutions will research
developing a combination therapy for immune gateway inhibitors. The agreement
came after the two parties signed a contract to co-develop STB001, an
immunotherapy agent developed using Syntekabio’s AI drug discovery platform.
“We will establish and
carry out a research strategy to maximize the therapeutic effect of the
candidate,” the company said. “Also, we will collaborate on new drug
development, including immunotherapy, using genome big data and AI models.”
CHA Hospital is an international medical
organization that operates 61 hospitals in seven countries, including the CHA
Bundang Hospital, CHA Gangnam Medical Center, CHA GUMI Medical Center, in
Korea, and other hospitals in the U.S., Australia, and Singapore.
Professors Jeon Hong-jae and Kim Chan, a
leading cancer researcher at CHA Bundang Hospital, are experts in the field of
immunotherapy drugs. He is actively conducting academic consultations and early
clinical trials for developing new anticancer drugs.
They have developed and published new
immunotherapeutic methods using STING and anticancer viruses in prominent
international journals, and are actively conducting academic advisory and
initial clinical trials for the development of new global anticancer drugs.
Syntekabio is discovering new drug
candidates using genome big data and AI, developing biomarkers to increase
clinical trial success rates, and providing genome precision medical services.
